Scion Asset Management’s Theravance Biopharma TBPH Stock Holding History

Scion Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-325,000	Closed	-$7.37M	–	7
2016 Q2	$7.37M	Buy	325,000 +50,000	+18%	+$1.08M	16.21%	4
2016 Q1	$5.17M	Sell	275,000 -161,626	-37%	-$2.64M	10.12%	7
2015 Q4	$7.16M	Buy	+436,626	New	+$6.93M	8.95%	3

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Scion Asset Management's TBPH Position: Q3 2016 in Review

Scion Asset Management sold out of Theravance Biopharma (TBPH) in Q3 2016, closing a stake of 325,000 shares — an estimated $7.37M sold.

Scion Asset Management first reported a position in TBPH in Q4 2015 and held it in 3 quarters. The position peaked at $7.37M in Q2 2016. 100 funds tracked by Wall St. Rank hold TBPH as of Q3 2016.

Scion Asset Management reported no remaining Theravance Biopharma position as of Q3 2016 after selling out during the quarter.
Scion Asset Management sold 325,000 Theravance Biopharma shares in Q3 2016, an estimated $7.37M.
Scion Asset Management first reported a position in Theravance Biopharma in Q4 2015 and held it in 3 quarters.
Scion Asset Management's Theravance Biopharma position peaked at $7.37M in Q2 2016.
100 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2016.

Based on Scion Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.